Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction

EuroIntervention 2019;14:1668-1675 published online November 2018. DOI: 10.4244/EIJ-D-18-00885

Francisco J. Morales-Ponce
Francisco J. Morales-Ponce1*, MD, PhD; Francisco J. Lozano-Cid1, MD; Pedro Martinez-Romero1, MD; Pablo Gonzalez-Perez1, MD; Juan A. Sanchez-Brotons1, MD; Isabel Diaz-Torres2, MD; Juan C. Rodriguez-Yanez2, MD, PhD; Pilar Caro-Mateo3, MD; Ana M. Serrador-Frutos4, MD, PhD
1. Department of Cardiology, Puerto Real University Hospital, Cadiz, Spain; 2. Critical Care Unit, Puerto Real University Hospital, Cadiz, Spain; 3. Department of Radiology, DADISA Radiological Center, Cadiz, Spain; 4. Department of Cardiology, Valladolid University Hospital, Valladolid, Spain

Aims: We sought to compare the effects of intracoronary administration of a fibrinolytic drug (tenecteplase) to those of a glycoprotein IIb/IIIa inhibitor (abciximab) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).

Methods and results: In this pilot trial, 76 patients (59 male) with anterior STEMI were randomised to intracoronary infusion of reduced-dose tenecteplase or abciximab during PPCI. Angiography was repeated at 48 hours to assess corrected TIMI frame count (cTFC) and TIMI myocardial perfusion grade (TMPG). The primary endpoint was infarct size as assessed by cardiac MRI. The abciximab group showed lower cTFC (median 14.1 [IQR 9.4-17.1]) than the tenecteplase group (18.2 [10.0-28.2]) (p=0.02), and the proportion of patients with TMPG grade 2/3 was higher in the abciximab group (90.3% vs. 67.7%; p=0.03). Major cardiac and cerebrovascular event rates did not differ; however, notably, 2/38 patients in the tenecteplase group experienced subacute stent thrombosis. At four months, there were no significant differences in infarct size between the tenecteplase and abciximab groups (17.0 g [9.6-27.5] vs. 21.1 g [11.3-35.0], p=0.33).

Conclusions: Intracoronary administration of tenecteplase did not reduce infarct size compared to abciximab in STEMI patients undergoing PPCI. Tenecteplase exhibited poorer myocardial reperfusion and might be associated with increased subacute stent thrombosis.

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapyclinical trialsmyocardial infarctionstemi
Coronary interventionsSTEMIOther coronary interventions
Read next article
Significant association among residual SYNTAX score, non-culprit major adverse cardiac events, and greyscale and virtual histology intravascular ultrasound findings: a substudy from the PROSPECT study

Latest news